The HLA-C knockout HeLa polyclonal cells are a CRISPR/Cas9-edited polyclonal population derived from the HeLa cell line, providing a loss-of-function model through target-gene disruption. This heterogeneous pool of knockout cells enables investigation of gene function without single-cell cloning bias, making it suitable for studies requiring population-level responses. The CRISPR/Cas9-mediated gene disruption abrogates HLA-C expression, allowing researchers to interrogate the roles of this MHC class I molecule in immune recognition and cancer biology.
The HeLa cell line is an immortalized human cervical adenocarcinoma epithelial line that contains integrated human papillomavirus 18 (HPV-18) DNA, originally isolated from a 31-year-old African-American woman. HeLa cells serve as a fundamental model in cancer research, cell signaling, and toxicology due to their robust growth and well-characterized genomic landscape. The constitutive expression of HPV-18 E6 and E7 oncoproteins, which disrupt p53 and retinoblastoma pathways, makes HeLa an ideal system for examining how tumor cells interact with the immune system.
HLA-C encodes the heavy chain of the polymorphic MHC class I molecule, presenting intracellular peptides to CD8+ T cells via its heavy chain binding to beta-2-microglobulin (B2M) and antigenic peptides. This process requires a peptide-loading complex including TAP1/TAP2, tapasin (TAPBP), calreticulin (CALR), and ERp57 (PDIA3). Expression is regulated by IFNG, NLRC5, IRF1, STAT1, and NF-kB. On the cell surface, HLA-C serves as a ligand for CD8 coreceptors on T cells and KIR2DL1/2/3 inhibitory and KIR2DS1/2 activating receptors on NK cells, as well as LILRB1 (ILT2) on macrophages. CRISPR/Cas9-mediated knockout ablates surface HLA-C, removing inhibitory signals to NK cells and impairing CD8+ T cell recognition, thus perturbing immune surveillance.
In HeLa cells, which harbor HPV-18 and originate from cervical carcinoma, HLA-C knockout enables dissection of MHC-I-mediated immune evasion. The loss of HLA-C potentiates NK cell-mediated killing by reducing engagement of inhibitory KIRs, while simultaneously attenuating CD8+ T cell responses to viral or tumor antigens. This dual effect on innate and adaptive immunity allows researchers to study tumor immune escape and identify compensatory mechanisms that maintain evasion. Such insights are valuable for designing immunotherapeutic strategies that modulate MHC-I expression.
This polyclonal knockout model supports applications in NK cell education, cancer immunity, and antiviral studies. It is compatible with a wide range of assays, including flow cytometry, Western blotting, RT-qPCR, NK cytotoxicity and T cell activation assays, co-immunoprecipitation, immunofluorescence, and mass spectrometry-based immunopeptidomics. The cells can also be used for drug target validation and peptide presentation screening. For additional details, please contact Ascent Research.
